Princeton rolls out Novartis' Bexsero; Mylan's Coury explains India strategy; Covidien swallowing PillCam maker;

@FiercePharma: ICYMI Friday: The Adcock Ingram sale gets messier, with Bidvest upping stake to block $1.2B CFR Pharma buyout. More | Follow @FiercePharma

@EricPFierce: Former Actavis CEO Robert Wessman gets Iceland to invest $250M in his biosimilars aspirations. Friday's story | Follow @EricPFierce

@CarlyHFierce: Pentagon tasks Pfizer with radically rethinking vaccine development. Story from FierceVaccines | Follow @CarlyHFierce

> The FDA has allowed Princeton University today to start a vaccination program for students using Novartis' ($NVS) meningitis B vaccine Bexsero, which is approved in Europe, Australia and Canada but not yet in the U.S. Release

> The strain of bacterial meningitis that has infected 8 students at Princeton University has also infected four students at the University of California, Santa Barbara, although that college has not yet moved to vaccinate students with Novartis' Bexsero. Story

> Lawyers for former SAC fund manager Mathew Martoma, named in a $276 million insider trading case, claim testimony by SAC Capital Advisors founder Steven Cohen shows their client wasn't involved in the alleged scheme. Story

> Mylan ($MYL) Chairman Robert Coury and President Rajiv Malik say their strategy in India has been to grow organically as well as through acquisitions. Q&A

> Teva Pharmaceutical Industries ($TEVA) says by 2018 its pipeline of new drugs could be producing between $1 billion and $1.5 billion in sales. Story

Medical Device News

@FierceMedDev: Covidien is acquiring Given Imaging, maker of the 'PillCam' oral endoscope, for $860M. More | Follow @FierceMedDev

@MarkHFierce: Zoll won Japanese approval for a next-gen monitor/defibrillator, marking its continued expansion in a giant HC mkt. Release | Follow @MarkHFierce

@MichaelGFierce: IT firm Cerner invests in Dx maker Claritas Genomics. Item | Follow @MichaelGFierce

@GalenMoore: Had breakfast yet? Here's a video of Pillcam's journey through the colon. Video | Follow @GalenMoore

> FDA asserts support for consumer genetic tests despite 23andMe crackdown. More

> Robert Langer co-founds a French wound-closure startup with a $10.8M Series A. Story

> Boston Scientific's departing CFO leads massive exec stock sell-off. Article

Biotech News

@FierceBiotech: 2013 American Society of Hematology annual meeting roundup: AbbVie, Gilead join Novartis in the center ring. Coverage | Follow @FierceBiotech

@JohnCFierce: Biogen forges a $200M preclinical Alzheimer's drug deal with Proteostasis. Story | Follow @JohnCFierce

@DamianFierce: "People who should have died 5 yrs ago are alive and well and in complete remission. It's a huge... shift." Story from Bloomberg | Follow @DamianFierce

@EmilyMFierce: A dried-up antibiotics pipeline has led two scientists to launch a crowdsourcing campaign for antibiotics research. Story | Follow @EmilyMFierce

> Novartis/Penn's customized T cell wows ASH with stellar leukemia data. More

> New era for hep C treatment begins with FDA OK for Gilead's sofosbuvir. Article

> Novartis is budgeting $6B a year for bolt-ons. Item

CRO News

> Sarah Cannon buys a clinical trial outfit to expand its cancer reach. Story

> Fast-growing Agilux doubles its preclinical space. News

> Venn snags an Irish CRO in its global buyout push. Report

> Charles River recruits Sloan-Kettering CEO to bolster its science. More

> Pfizer's unlocked trial data could be a boon to CROs. Article

> Sluggish Parexel could be poised for a long-term turnaround. Item

Biotech IT News

> Pfizer is opening up clinical trial data to researchers, patients starting in 2014. Report

> Wanted: 1,000 citizen scientists to crowdsource antibiotics research. Story

> Report tips analytics to get biopharma out of its productivity slump. News

> U.K. sets up $16M competition to find genome data analysis tools. Article

> Text mining 88,000 papers gives Pfizer a drug safety database. More

> Machine learning improves accuracy of flu forecasts. Item

And Finally... Covidien ($COV) will pay $860 million to buy Israel-based Given Imaging ($GIVN), which makes PillCam, the encapsulated endoscope that patients swallow. Story

Suggested Articles

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.